share_log

Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.5

Moomoo 24/7 ·  Apr 19 10:38

Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $7 to $2.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment